Leading online mental health care service platform, Cerebral Inc. has announced on Wednesday that it will be halting the prescription of two popular ADHD medications, Adderall and Ritalin for new patients starting Monday, May 9.

Cerebral founder and CEO, Kyle Robertson says the reason for the pause is because of Cerebral's mission of clinical quality and safety.

"Based on recent feedback from stakeholders, it is clear that this has become a distraction from our focus to democratize access to mental health care services, provide treatment for more patients and add service lines for new conditions," Robertson said.

Chief Medical Officer and President of Cerebral, Dr. David Mou added that he feels it's "regrettable" that medications such as these have become stigmatized.

"We hope this will change as a population of people with clinical needs are no longer able to access care with us," Mou said.

In addition, Cerebral is adding more safeguards to its clinical safety protocols including additional assessment capabilities such as urine drug screenings to further equip clinicians with more info on their patients.

Cerebral has also instituted more effective communication channels with clinicians and coordinators to ensure their feedback is acknowledged and addressed.

Additionally, the company is developing new tools for its electronic medical records to increase efficiency in identifying and sending critical information to clinicians, as well as new quantitative measurement tools for its systems to better track the potential positive impact of its clinical quality and safety.

This pause will not affect current patients who have already been prescribed either of the two medications. Cerebral will work to create a smooth transition for its care professionals and impacted patients.